GenSight falls after Phase III neuropathy miss

GenSight Biologics S.A. (Euronext:SIGHT) fell €2.71 (48%) to €2.97 on Wednesday after reporting that GS010 (rAAV2/2-ND4) missed the primary endpoint of improving visual acuity in the Phase

Read the full 274 word article

User Sign In